Read by QxMD icon Read

Seminars in Thrombosis and Hemostasis

Catherine P M Hayward, Georges E Rivard
No abstract text is available yet for this article.
January 14, 2019: Seminars in Thrombosis and Hemostasis
Jecko Thachil
Disseminated intravascular coagulation (DIC) is an intermediary mechanism of disease known to develop as a complication in other conditions like sepsis, trauma, cancer, or obstetrical disorders. Patients with DIC may present to different specialists depending on symptomology and as such a good understanding of the pathophysiological process is necessary to ensure best management. However, more recently, controversy has risen where experts doubt whether DIC really exists in many of the historically well-established diagnoses...
January 11, 2019: Seminars in Thrombosis and Hemostasis
Elodie Laridan, Kimberly Martinod, Simon F De Meyer
Thrombotic complications are still a major health risk worldwide. Our view on the pathophysiology of thrombosis has significantly changed since the discovery of neutrophil extracellular traps (NETs) and their prothrombotic characteristics. Generated by neutrophils that release their decondensed chromatin as a network of extracellular fibers, NETs promote thrombus formation by serving as a scaffold that activates platelets and coagulation. The thrombogenic involvement of NETs has been described in various settings of thrombosis, including stroke, myocardial infarction, and deep vein thrombosis...
January 11, 2019: Seminars in Thrombosis and Hemostasis
Kylee H Maclachlan, Hannah P Stevens, Huyen A Tran, Sanjeev D Chunilal
In trials assessing venous thromboembolism (VTE) treatment, obese patients are under-represented or excluded. The main objective of this article is to examine the safety of weight-based enoxaparin dosing in obesity, as assessed by anti-factor Xa (anti-Xa) activity, bleeding, and recurrence. A 5-year retrospective audit of patients with acute VTE, weighing > 100 kg, prescribed enoxaparin 1 mg/kg twice daily, with an anti-Xa level 2 to 6 hours post-dose. The primary outcome was anti-Xa levels, and the secondary outcomes were bleeding and recurrence...
January 10, 2019: Seminars in Thrombosis and Hemostasis
Peter Kubisz, Pavol Holly, Jan Stasko
Since the identification of antithrombin deficiency by Egeberg in 1956, ongoing research in prothrombotic defects continues to progress. Interestingly, past research has predominantly focused on coagulation factors and not on other components of the hemostatic system. The possible role of platelet function defects in the development of thrombotic events was suggested for the first time in the late 1970s, when an increased platelet adhesiveness and aggregation after epinephrine (EPI) and adenosine diphosphate (ADP) was found in a group of patients with unexplained transient ischemic attack...
January 10, 2019: Seminars in Thrombosis and Hemostasis
Emmanuel J Favaloro, Geoffrey Kershaw, Soma Mohammed, Giuseppe Lippi
The activated partial thromboplastin time (APTT) assay is a very common coagulation test, used for several reasons. The test is conventionally used for assessing the contact factor (intrinsic) pathway of blood coagulation, and thus for screening deficiencies in this pathway, most typically factors VIII, IX, and XI. The APTT is also sensitive to contact factor deficiencies, including factor XII, prekallikrein, and high-molecular-weight kininogen. The APTT may also be elevated in a variety of conditions, including liver disease, vitamin K deficiency, and disseminated intravascular coagulation...
January 10, 2019: Seminars in Thrombosis and Hemostasis
Akbar Dorgalaleh, Shadi Tabibian, Mahmood Shams, Golbahar Majid, Majid Naderi, Alessandro Casini, Behnaz Tavasoli, Maryam Gheidishiran, Maryam Daneshi, Majid Safa
Congenital factor XIII (FXIII) deficiency is an extremely rare hemorrhagic disorder characterized by a deficiency of FXIII and associated with a high rate of morbidity and mortality. The disorder is more frequent in Iran, especially in Khash, a city in the southeast of the country. As identified in the current report, the prevalence of FXIII deficiency in this city is 1 homozygote per approximately 500 population (which is ∼4,000 times higher than the worldwide prevalence) with 3.5% heterozygotes. The disorder is accompanied by a high rate of mortality in rural areas of Khash, given an averaged observed rate of approximately three deaths per each family with FXIII deficiency, mostly due to late-diagnosis and/or misdiagnosis, and fetal consequences of both umbilical cord and central nervous system bleeding...
January 10, 2019: Seminars in Thrombosis and Hemostasis
Meera Sridharan, Lea M Coon, Dong Chen, Rajiv K Pruthi
No abstract text is available yet for this article.
January 10, 2019: Seminars in Thrombosis and Hemostasis
Emmanuel J Favaloro, Giuseppe Lippi
No abstract text is available yet for this article.
January 10, 2019: Seminars in Thrombosis and Hemostasis
Evelyn Kendall Williams, Oluwamayokun Oshinowo, Abhijit Ravindran, Wilbur A Lam, David R Myers
In addition to the classical biological and biochemical framework, blood clots can also be considered as active biomaterials composed of dynamically contracting platelets, nascent polymeric fibrin that functions as a matrix scaffold, and entrapped blood cells. As platelets sense, rearrange, and apply forces to the surrounding microenvironment, they dramatically change the material properties of the nascent clot, increasing its stiffness by an order of magnitude. Hence, the mechanical properties of blood clots are intricately tied to the forces applied by individual platelets...
December 19, 2018: Seminars in Thrombosis and Hemostasis
Ming Sheng Lim, Tishya Indran, Anita Cummins, Ashwini Bennett, Erica Wood, Susan Brown, Zoe McQuilten, Huyen Tran, Master Clin Epi, Noel C Chan, Sanjeev Chunilal
The highest risk of adverse events for patients with acute venous thromboembolism (VTE) is during the early anticoagulation period. However, no established model exists for early clinical monitoring of patients treated with non-vitamin K antagonist oral anticoagulants (NOACs). The authors' aim was to evaluate the utility of a nurse-led pathway to minimize adverse events in acute VTE patients starting on rivaroxaban. The rivaroxaban VTE treatment pathway is a prospective cohort study of consecutive patients with objectively confirmed VTE between July 2015 and May 2017...
December 19, 2018: Seminars in Thrombosis and Hemostasis
Eugene S Krauss, MaryAnne Cronin, Nancy Dengler, Barry G Simonson, Kathleen Altner, Madison Daly, Ayal Segal
Rivaroxaban is approved in Europe and the United States for thromboprophylaxis following total joint arthroplasty. As the rate of obesity increases, confirming safety and efficacy in this patient population is paramount. This retrospective chart review assessed the efficacy and safety of rivaroxaban between two body mass index (BMI) groups: normal or overweight (< 30 kg/m2 ) and obese or morbidly obese (≥30 kg/m2 ). Safety outcome was a major bleeding event, defined as a decrease in hemoglobin of at least 2 g/dL from postoperative day 1(POD 1) to discharge or a blood transfusion of at least two units...
December 19, 2018: Seminars in Thrombosis and Hemostasis
Brandon S Jackson, Etheresia Pretorius
The number of people infected with human immunodeficiency virus (HIV) is rapidly increasing and the majority of those infected are living in sub-Saharan Africa. Some hallmarks of HIV are inflammation and upregulation of inflammatory markers. A pathological coagulation system may accompany these inflammatory changes and potentially result in venous thromboembolism such as a deep vein thrombosis (DVT). In this review, the authors describe the inflammatory profile in HIV, the treatment regimens currently in place in South Africa, and in particular how HIV affects the hematological system, with specific focus on platelets, red blood cells (RBCs; erythrocytes), and fibrin(ogen)...
December 19, 2018: Seminars in Thrombosis and Hemostasis
Joanna Yilin Huang, Diajeng Ayesha Soeharto, Ivan Damara, Vera Ignjatovic, Matthew D Linden, Paul Monagle
Antiplatelet agents are used for the prevention and treatment of thromboembolic disease in an increasingly complex population of pediatric patients. Despite their importance for clinical outcome, there is no consensus on the most effective monitoring strategies. This review describes the current state of knowledge focusing on antiplatelet therapy monitoring in children. The authors searched five databases (PubMed-NCBI, MEDLINE-OVID, SCOPUS-Elsevier, ScienceDirect, and Cochrane) from January 2000 to October 2017 using keywords selected a priori ...
December 19, 2018: Seminars in Thrombosis and Hemostasis
Sebastian Harder, Sascha Meyer Dos Santos, Viktor Krozer, Jochen Moll
An universal coagulation test that reliably detects prolonged coagulation times in patients, regardless of which anticoagulant is administered, is not yet available. The authors developed a novel, miniaturized device utilizing surface acoustic waves (SAW) to detect clotting, and used it to develop a novel universal microfluidic coagulation test. Results from this assay were compared with results from standard coagulation assays to detect classical anticoagulants (unfractionated heparin, argatroban) and direct oral anticoagulants (dabigatran, rivaroxaban)...
December 19, 2018: Seminars in Thrombosis and Hemostasis
Jack Ansell, Stefan Zappe, Xuan Jiang, Lirong Chen, Solomon Steiner, Bryan Laulicht, Sasha Bakhru
The direct oral anticoagulants (DOACs) currently require no monitoring for routine therapy of atrial fibrillation or venous thromboembolism. Measurement of activity, however, may be important in patients with major and life-threatening bleeding, patients needing emergent surgery, in reversal situations, or in patients at high risk of bleeding or thrombosis due to underlying conditions. For these patients, a widely available and rapid turnaround assay would be optimal. To date, there is no such assay available, especially for the direct factor Xa inhibitors...
December 19, 2018: Seminars in Thrombosis and Hemostasis
Lucia Stanciakova, Peter Kubisz, Jan Stasko, Jaroslav Maly
No abstract text is available yet for this article.
December 19, 2018: Seminars in Thrombosis and Hemostasis
Giuseppe Lippi, Elisa Danese, Emmanuel J Favaloro
Aspirin is one of the most often used drugs for prevention and treatment of a variety of thrombotic disorders. This narrative review aims to provide an overview of evidence highlighting potential benefits and relative harms of aspirin in primary prevention of cardiovascular disease. The authors summarize key findings of the ASPirin in Reducing Events in the Elderly (ASPREE) Investigator Group randomized trial and also provide a comparative overview of recent meta-analyses. Overall, all-cause mortality was largely heterogeneous, with some meta-analyses showing a modestly decreased risk in patients taking aspirin, with others reporting no effects, but the ASPREE Investigator Group trial evidencing 14% higher risk...
October 22, 2018: Seminars in Thrombosis and Hemostasis
Murray J Adams, James W Fell
No abstract text is available yet for this article.
November 2018: Seminars in Thrombosis and Hemostasis
Eva Zetterberg, Marcus Ljungkvist, Maryem Salim
Sports and strenuous exercise have traditionally been discouraged for people with hemophilia (PWH) because of the perceived risk of bleeding. In this review, studies investigating the pros and cons of exercise are presented, and although most studies are of low validity, the randomized trials that do exist tell us that PWH benefit from exercise in terms of improved muscular function, endurance, and quality of life and that increased bleeding does not seem to be an issue. The authors also review the studies that have analyzed the current physical status of PWH compared with the general population in different countries...
November 2018: Seminars in Thrombosis and Hemostasis
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"